Altered distribution of caveolin-1 in early liver steatosis

European Journal of Clinical Investigation

Volumn 41, Issue 6, 2011, Pages 642-651

  Mastrodonato, Maria ^a   Calamita, Giuseppe ^a   Rossi, Roberta ^a   Mentino, Donatella ^a   Bonfrate, Leonilde ^a   Portincasa, Piero ^a   Ferri, Domenico ^a   Liquori, Giuseppa E ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Choline deficient diet; Fatty liver; Immunoblotting; Immunohistochemistry; Metabolic syndrome

Indexed keywords

CAVEOLIN 1; CHOLINE; FAT DROPLET;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOLATERAL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ELECTRON MICROSCOPY; FATTY LIVER; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LIPOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER MEMBRANE; METABOLIC SYNDROME X; MITOCHONDRIAL MEMBRANE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RISK FACTOR; WESTERN BLOTTING;

ANIMALS; CAVEOLIN 1; CHOLINE; DIET; FATTY LIVER; IMMUNOBLOTTING; MALE; RATS; RATS, WISTAR; STATISTICS AS TOPIC;

EID: 79955599893     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02459.x     Document Type: Article

References (59)

1. Chidlow JH Jr, Sessa WC. Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation. Cardiovasc Res 2010;86:219-25.
2. Lajoie P, Goetz JG, Dennis JW, Nabi IR. Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol 2009;185:381-5.
3. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 1998;273:5419-22.
4. Liquori GE, Caroppo R, Mastrodonato M, Scillitani G, Ferri D. Co-secretion of soluble caveolin-1 and pepsinogen in the oesophagus of the red-legged frog Rana aurora aurora. Acta Histochem 2004;106:21-7.
5. Robenek MJ, Severs NJ, Schlattmann K, Plenz G, Zimmer KP, Troyer D et al. Lipids partition caveolin-1 from ER membranes into lipid droplets: updating the model of lipid droplet biogenesis. FASEB J 2004;18:866-8.
6. Podar K, Anderson KC. Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Lett 2006;233:10-5.
7. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 2002;277:8635-47.
8. Murata M, Peranen J, Schreiner R, Wieland F, Kurzchalia TV, Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci U S A 1995;92:10339-43.
9. Li S, Song KS, Lisanti MP. Expression and characterization of recombinant caveolin. Purification by polyhistidine tagging and cholesterol-dependent incorporation into defined lipid membranes. J Biol Chem 1996;271:568-73.
10. Smart EJ, Ying Y, Donzell WC, Anderson RG. A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J Biol Chem 1996;271:29427-35.
11. Liu P, Li WP, Machleidt T, Anderson RG. Identification of caveolin-1 in lipoprotein particles secreted by exocrine cells. Nat Cell Biol 1999;1:369-75.
12. Trigatti BL, Anderson RG, Gerber GE. Identification of caveolin-1 as a fatty acid binding protein. Biochem Biophys Res Commun 1999;255:34-9.
13. Le LS, Blouin CM, Hajduch E, Dugail I. Filling up adipocytes with lipids. Lessons from caveolin-1 deficiency. Biochim Biophys Acta 2009;1791:514-8.
14. Tauchi-Sato K, Ozeki S, Houjou T, Taguchi R, Fujimoto T. The surface of lipid droplets is a phospholipid monolayer with a unique Fatty Acid composition. J Biol Chem 2002;277:44507-12.
15. Fujimoto T, Kogo H, Ishiguro K, Tauchi K, Nomura R. Caveolin-2 is targeted to lipid droplets, a new "membrane domain" in the cell. J Cell Biol 2001;152:1079-85.
16. Ostermeyer AG, Paci JM, Zeng Y, Lublin DM, Munro S, Brown DA. Accumulation of caveolin in the endoplasmic reticulum redirects the protein to lipid storage droplets. J Cell Biol 2001;152:1071-8.
17. Pol A, Luetterforst R, Lindsay M, Heino S, Ikonen E, Parton RG. A caveolin dominant negative mutant associates with lipid bodies and induces intracellular cholesterol imbalance. J Cell Biol 2001;152:1057-70.
18. Li WP, Liu P, Pilcher BK, Anderson RG. Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J Cell Sci 2001;114:1397-408.
19. Fernandez MA, Albor C, Ingelmo-Torres M, Nixon SJ, Ferguson C, Kurzchalia T et al. Caveolin-1 is essential for liver regeneration. Science 2006;313:1628-32.
20. Frank PG, Lisanti MP. Caveolin-1 and liver regeneration: role in proliferation and lipogenesis. Cell Cycle 2007;6:115-6.
21. Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 2005;28:1518-23.
22. Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007;11:1231-49.
23. Woudenberg J, Rembacz KP, van den Heuvel FA, Woudenberg-Vrenken TE, Buist-Homan M, Geuken M et al. Caveolin-1 is enriched in the peroxisomal membrane of rat hepatocytes. Hepatology 2010;51:1744-53.
24. Natarajan SK, Eapen CE, Pullimood AB, Balasubramanian KA. Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes. J Gastroenterol Hepatol 2006;21:1240-9.
25. da Silva GH, Coelho KI, Coelho CA, Escanhoela CA. Mitochondrial alterations in nonalcoholic fatty liver disease. Pediatric case description of three submitted sequential biopsies. J Gastrointestin Liver Dis 2009;18:215-9.
26. Grattagliano I, Caraceni P, Portincasa P, Domenicali M, Palmieri VO, Trevisani F et al. Adaptation of subcellular glutathione detoxification system to stress conditions in choline-deficient diet induced rat fatty liver. Cell Biol Toxicol 2003;19:355-66.
27. Kulinski A, Vance DE, Vance JE. A choline-deficient diet in mice inhibits neither the CDP-choline pathway for phosphatidylcholine synthesis in hepatocytes nor apolipoprotein B secretion. J Biol Chem 2004;279:23916-24.
28. Raubenheimer PJ, Nyirenda MJ, Walker BR. A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes 2006;55:2015-20.
29. Graham RC Jr, Karnovsky MJ. The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histochem Cytochem 1966;14:291-302.
30. Mastrodonato M, Calamita G, Rossi R, Scillitani G, Liquori GE, Ferri D. Expression of H(+), K(+)-ATPase and glycopattern analysis in the gastric glands of Rana esculenta. J Histochem Cytochem 2009;57:215-25.
31. Reynolds ES. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol 1963;17:208-12.
32. Carreras FI, Gradilone SA, Mazzone A, Garcia F, Huang BQ, Ochoa JE et al. Rat hepatocyte aquaporin-8 water channels are down-regulated in extrahepatic cholestasis. Hepatology 2003;37:1026-33.
33. Calamita G, Ferri D, Gena P, Carreras FI, Liquori GE, Portincasa P et al. Altered expression and distribution of aquaporin-9 in the liver of rat with obstructive extrahepatic cholestasis. Am J Physiol Gastrointest Liver Physiol 2008;295:G682-90.
34. Liquori GE, Calamita G, Cascella D, Mastrodonato M, Portincasa P, Ferri D. An innovative methodology for the automated morphometric and quantitative estimation of liver steatosis. Histol Histopathol 2009;24:49-60.
35. Portincasa P, Grattagliano I, Lauterburg BH, Palmieri VO, Palasciano G, Stellaard F. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin Sci (Lond) 2006;111:135-43.
36. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Current pharmacological treatment of nonalcoholic fatty liver. Curr Med Chem 2006;13:2889-900.
37. Portincasa P. Non-alcoholic steatohepatitis (NASH): approaching more tailored and effective therapies. J Gastrointestin Liver Dis 2007;16:167-9.
38. Palasciano G, Moschetta A, Palmieri VO, Grattagliano I, Iacobellis G, Portincasa P. Non-alcoholic Fatty liver disease in the metabolic syndrome. Curr Pharm Des 2007;13:2193-8.
39. Petruzzelli M, Lo Sasso G, Portincasa P, Palasciano G, Moschetta A. Targeting the liver in the metabolic syndrome: evidence from animal models. Curr Pharm Des 2007;13:2199-207.
40. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008;19:491-504.
41. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006;368:230-9.
42. Grundy SM, Barnett JP. Metabolic and health complications of obesity. Dis Mon 1990;36:641-731.
43. Grundy SM. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol 2005;25:2243-4.
44. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
45. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
46. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr 2004;80:38-44.
47. Grattagliano I, Caraceni P, Calamita G, Ferri D, Gargano I, Palasciano G et al. Severe liver steatosis correlates with nitrosative and oxidative stress in rats. Eur J Clin Invest 2008;38:523-30.
48. Pacelli C, Coluccia A, Grattagliano I, Cocco T, Petrosillo G, Paradies G et al. Dietary choline deprivation impairs rat brain mitochondrial function and behavioral phenotype. J Nutr 2010;140:1072-9.
49. Petrosillo G, Portincasa P, Grattagliano I, Casanova G, Matera M, Ruggiero FM et al. Mitochondrial dysfunction in rat with nonalcoholic fatty liver Involvement of complex I, reactive oxygen species and cardiolipin. Biochim Biophys Acta 2007;1767:1260-7.
50. Mayoral R, Fernandez-Martinez A, Roy R, Bosca L, Martin-Sanz P. Dispensability and dynamics of caveolin-1 during liver regeneration and in isolated hepatic cells. Hepatology 2007;46:813-22.
51. Cohen AW, Schubert W, Brasaemle DL, Scherer PE, Lisanti MP. Caveolin-1 expression is essential for proper nonshivering thermogenesis in brown adipose tissue. Diabetes 2005;54:679-86.
52. Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 2008;44:1259-72.
53. Ferri D, Moro L, Mastrodonato M, Capuano F, Marra E, Liquori GE et al. Ultrastructural zonal heterogeneity of hepatocytes and mitochondria within the hepatic acinus during liver regeneration after partial hepatectomy. Biol Cell 2005;97:277-88.
54. Zhou YH, Shi D, Yuan B, Sun QJ, Jiao BH, Sun JJ et al. Mitochondrial ultrastructure & release of proteins during liver regeneration. Indian J Med Res 2008;128:157-64.
55. Hahn-Obercyger M, Graeve L, Madar Z. A high-cholesterol diet increases the association between caveolae and insulin receptors in rat liver. J Lipid Res 2009;50:98-107.
56. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 1996;271:22810-4.
57. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
58. Razani B, Lisanti MP. Caveolin-deficient mice: insights into caveolar function human disease. J Clin Invest 2001;108:1553-61.
59. Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE et al. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 2003;285:C222-35.